
A programmable tools used for CRISPER (clusters of regularly interspaced short palindromic repeats), which could mediate targeted DNA or RNA cleavage. These sepecific endonuclease drives targeted gene disruption through nonhomologous end joining (NHEJ) or precise gene editing through template-dependent homology-directed repair (HDR).
The global CRISPER-associated Nucleases market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
Key manufacturers engaged in the CRISPER-associated Nucleases industry include The Odin, Origene, Amsbio, Thermo Fisher Scientific, Merck, Boai Nky Medical Holdings Ltd, Biocompare, BioLabs, Inc. and Inscripta, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of CRISPER-associated Nucleases were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CRISPER-associated Nucleases market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CRISPER-associated Nucleases market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
The Odin
Origene
Amsbio
Thermo Fisher Scientific
Merck
Boai Nky Medical Holdings Ltd
Biocompare
BioLabs, Inc.
Inscripta
Sherlock Biosciences
Editas
CRISPR Therapeutics
Synthego
Addgene
IDT (Integrated DNA Technologies)
Horizon Discovery
ToolGen
GenScript
New England Biolabs (NEB)
Segment by Type
CRISPER-associated Protein 9 (Cas 9)
Cpf 1
CRISPER-associated Protein 13 (Cas 13)
Segment by Application
DNA Editing
RNA Editing
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The CRISPER-associated Nucleases report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Âé¶¹Ô´´ Channel and Customer Analysis
Chapter 8: Âé¶¹Ô´´ Opportunities and Challenges
Chapter 9: Âé¶¹Ô´´ Conclusions
Chapter 10: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 CRISPER-associated Nucleases Âé¶¹Ô´´ Overview
1.1 Product Overview and Scope of CRISPER-associated Nucleases
1.2 CRISPER-associated Nucleases Segment by Type
1.2.1 Global CRISPER-associated Nucleases Âé¶¹Ô´´ Value Comparison by Type (2023-2029)
1.2.2 CRISPER-associated Protein 9 (Cas 9)
1.2.3 Cpf 1
1.2.4 CRISPER-associated Protein 13 (Cas 13)
1.3 CRISPER-associated Nucleases Segment by Application
1.3.1 Global CRISPER-associated Nucleases Âé¶¹Ô´´ Value by Application: (2023-2029)
1.3.2 DNA Editing
1.3.3 RNA Editing
1.4 Global CRISPER-associated Nucleases Âé¶¹Ô´´ Size Estimates and Forecasts
1.4.1 Global CRISPER-associated Nucleases Revenue 2018-2029
1.4.2 Global CRISPER-associated Nucleases Sales 2018-2029
1.4.3 Global CRISPER-associated Nucleases Âé¶¹Ô´´ Average Price (2018-2029)
1.5 Assumptions and Limitations
2 CRISPER-associated Nucleases Âé¶¹Ô´´ Competition by Manufacturers
2.1 Global CRISPER-associated Nucleases Sales Âé¶¹Ô´´ Share by Manufacturers (2018-2023)
2.2 Global CRISPER-associated Nucleases Revenue Âé¶¹Ô´´ Share by Manufacturers (2018-2023)
2.3 Global CRISPER-associated Nucleases Average Price by Manufacturers (2018-2023)
2.4 Global CRISPER-associated Nucleases Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of CRISPER-associated Nucleases, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CRISPER-associated Nucleases, Product Type & Application
2.7 CRISPER-associated Nucleases Âé¶¹Ô´´ Competitive Situation and Trends
2.7.1 CRISPER-associated Nucleases Âé¶¹Ô´´ Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CRISPER-associated Nucleases Players Âé¶¹Ô´´ Share by Revenue
2.7.3 Global CRISPER-associated Nucleases Âé¶¹Ô´´ Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CRISPER-associated Nucleases Retrospective Âé¶¹Ô´´ Scenario by Region
3.1 Global CRISPER-associated Nucleases Âé¶¹Ô´´ Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global CRISPER-associated Nucleases Global CRISPER-associated Nucleases Sales by Region: 2018-2029
3.2.1 Global CRISPER-associated Nucleases Sales by Region: 2018-2023
3.2.2 Global CRISPER-associated Nucleases Sales by Region: 2024-2029
3.3 Global CRISPER-associated Nucleases Global CRISPER-associated Nucleases Revenue by Region: 2018-2029
3.3.1 Global CRISPER-associated Nucleases Revenue by Region: 2018-2023
3.3.2 Global CRISPER-associated Nucleases Revenue by Region: 2024-2029
3.4 North America CRISPER-associated Nucleases Âé¶¹Ô´´ Facts & Figures by Country
3.4.1 North America CRISPER-associated Nucleases Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America CRISPER-associated Nucleases Sales by Country (2018-2029)
3.4.3 North America CRISPER-associated Nucleases Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe CRISPER-associated Nucleases Âé¶¹Ô´´ Facts & Figures by Country
3.5.1 Europe CRISPER-associated Nucleases Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe CRISPER-associated Nucleases Sales by Country (2018-2029)
3.5.3 Europe CRISPER-associated Nucleases Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CRISPER-associated Nucleases Âé¶¹Ô´´ Facts & Figures by Country
3.6.1 Asia Pacific CRISPER-associated Nucleases Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific CRISPER-associated Nucleases Sales by Country (2018-2029)
3.6.3 Asia Pacific CRISPER-associated Nucleases Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America CRISPER-associated Nucleases Âé¶¹Ô´´ Facts & Figures by Country
3.7.1 Latin America CRISPER-associated Nucleases Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America CRISPER-associated Nucleases Sales by Country (2018-2029)
3.7.3 Latin America CRISPER-associated Nucleases Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CRISPER-associated Nucleases Âé¶¹Ô´´ Facts & Figures by Country
3.8.1 Middle East and Africa CRISPER-associated Nucleases Âé¶¹Ô´´ Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa CRISPER-associated Nucleases Sales by Country (2018-2029)
3.8.3 Middle East and Africa CRISPER-associated Nucleases Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global CRISPER-associated Nucleases Sales by Type (2018-2029)
4.1.1 Global CRISPER-associated Nucleases Sales by Type (2018-2023)
4.1.2 Global CRISPER-associated Nucleases Sales by Type (2024-2029)
4.1.3 Global CRISPER-associated Nucleases Sales Âé¶¹Ô´´ Share by Type (2018-2029)
4.2 Global CRISPER-associated Nucleases Revenue by Type (2018-2029)
4.2.1 Global CRISPER-associated Nucleases Revenue by Type (2018-2023)
4.2.2 Global CRISPER-associated Nucleases Revenue by Type (2024-2029)
4.2.3 Global CRISPER-associated Nucleases Revenue Âé¶¹Ô´´ Share by Type (2018-2029)
4.3 Global CRISPER-associated Nucleases Price by Type (2018-2029)
5 Segment by Application
5.1 Global CRISPER-associated Nucleases Sales by Application (2018-2029)
5.1.1 Global CRISPER-associated Nucleases Sales by Application (2018-2023)
5.1.2 Global CRISPER-associated Nucleases Sales by Application (2024-2029)
5.1.3 Global CRISPER-associated Nucleases Sales Âé¶¹Ô´´ Share by Application (2018-2029)
5.2 Global CRISPER-associated Nucleases Revenue by Application (2018-2029)
5.2.1 Global CRISPER-associated Nucleases Revenue by Application (2018-2023)
5.2.2 Global CRISPER-associated Nucleases Revenue by Application (2024-2029)
5.2.3 Global CRISPER-associated Nucleases Revenue Âé¶¹Ô´´ Share by Application (2018-2029)
5.3 Global CRISPER-associated Nucleases Price by Application (2018-2029)
6 Key Companies Profiled
6.1 The Odin
6.1.1 The Odin Corporation Information
6.1.2 The Odin Description and Business Overview
6.1.3 The Odin CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.1.4 The Odin CRISPER-associated Nucleases Product Portfolio
6.1.5 The Odin Recent Developments/Updates
6.2 Origene
6.2.1 Origene Corporation Information
6.2.2 Origene Description and Business Overview
6.2.3 Origene CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Origene CRISPER-associated Nucleases Product Portfolio
6.2.5 Origene Recent Developments/Updates
6.3 Amsbio
6.3.1 Amsbio Corporation Information
6.3.2 Amsbio Description and Business Overview
6.3.3 Amsbio CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Amsbio CRISPER-associated Nucleases Product Portfolio
6.3.5 Amsbio Recent Developments/Updates
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description and Business Overview
6.4.3 Thermo Fisher Scientific CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Thermo Fisher Scientific CRISPER-associated Nucleases Product Portfolio
6.4.5 Thermo Fisher Scientific Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Merck CRISPER-associated Nucleases Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Boai Nky Medical Holdings Ltd
6.6.1 Boai Nky Medical Holdings Ltd Corporation Information
6.6.2 Boai Nky Medical Holdings Ltd Description and Business Overview
6.6.3 Boai Nky Medical Holdings Ltd CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boai Nky Medical Holdings Ltd CRISPER-associated Nucleases Product Portfolio
6.6.5 Boai Nky Medical Holdings Ltd Recent Developments/Updates
6.7 Biocompare
6.6.1 Biocompare Corporation Information
6.6.2 Biocompare Description and Business Overview
6.6.3 Biocompare CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biocompare CRISPER-associated Nucleases Product Portfolio
6.7.5 Biocompare Recent Developments/Updates
6.8 BioLabs, Inc.
6.8.1 BioLabs, Inc. Corporation Information
6.8.2 BioLabs, Inc. Description and Business Overview
6.8.3 BioLabs, Inc. CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BioLabs, Inc. CRISPER-associated Nucleases Product Portfolio
6.8.5 BioLabs, Inc. Recent Developments/Updates
6.9 Inscripta
6.9.1 Inscripta Corporation Information
6.9.2 Inscripta Description and Business Overview
6.9.3 Inscripta CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Inscripta CRISPER-associated Nucleases Product Portfolio
6.9.5 Inscripta Recent Developments/Updates
6.10 Sherlock Biosciences
6.10.1 Sherlock Biosciences Corporation Information
6.10.2 Sherlock Biosciences Description and Business Overview
6.10.3 Sherlock Biosciences CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Sherlock Biosciences CRISPER-associated Nucleases Product Portfolio
6.10.5 Sherlock Biosciences Recent Developments/Updates
6.11 Editas
6.11.1 Editas Corporation Information
6.11.2 Editas CRISPER-associated Nucleases Description and Business Overview
6.11.3 Editas CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Editas CRISPER-associated Nucleases Product Portfolio
6.11.5 Editas Recent Developments/Updates
6.12 CRISPR Therapeutics
6.12.1 CRISPR Therapeutics Corporation Information
6.12.2 CRISPR Therapeutics CRISPER-associated Nucleases Description and Business Overview
6.12.3 CRISPR Therapeutics CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.12.4 CRISPR Therapeutics CRISPER-associated Nucleases Product Portfolio
6.12.5 CRISPR Therapeutics Recent Developments/Updates
6.13 Synthego
6.13.1 Synthego Corporation Information
6.13.2 Synthego CRISPER-associated Nucleases Description and Business Overview
6.13.3 Synthego CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Synthego CRISPER-associated Nucleases Product Portfolio
6.13.5 Synthego Recent Developments/Updates
6.14 Addgene
6.14.1 Addgene Corporation Information
6.14.2 Addgene CRISPER-associated Nucleases Description and Business Overview
6.14.3 Addgene CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Addgene CRISPER-associated Nucleases Product Portfolio
6.14.5 Addgene Recent Developments/Updates
6.15 IDT (Integrated DNA Technologies)
6.15.1 IDT (Integrated DNA Technologies) Corporation Information
6.15.2 IDT (Integrated DNA Technologies) CRISPER-associated Nucleases Description and Business Overview
6.15.3 IDT (Integrated DNA Technologies) CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.15.4 IDT (Integrated DNA Technologies) CRISPER-associated Nucleases Product Portfolio
6.15.5 IDT (Integrated DNA Technologies) Recent Developments/Updates
6.16 Horizon Discovery
6.16.1 Horizon Discovery Corporation Information
6.16.2 Horizon Discovery CRISPER-associated Nucleases Description and Business Overview
6.16.3 Horizon Discovery CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Horizon Discovery CRISPER-associated Nucleases Product Portfolio
6.16.5 Horizon Discovery Recent Developments/Updates
6.17 ToolGen
6.17.1 ToolGen Corporation Information
6.17.2 ToolGen CRISPER-associated Nucleases Description and Business Overview
6.17.3 ToolGen CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.17.4 ToolGen CRISPER-associated Nucleases Product Portfolio
6.17.5 ToolGen Recent Developments/Updates
6.18 GenScript
6.18.1 GenScript Corporation Information
6.18.2 GenScript CRISPER-associated Nucleases Description and Business Overview
6.18.3 GenScript CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.18.4 GenScript CRISPER-associated Nucleases Product Portfolio
6.18.5 GenScript Recent Developments/Updates
6.19 New England Biolabs (NEB)
6.19.1 New England Biolabs (NEB) Corporation Information
6.19.2 New England Biolabs (NEB) CRISPER-associated Nucleases Description and Business Overview
6.19.3 New England Biolabs (NEB) CRISPER-associated Nucleases Sales, Revenue and Gross Margin (2018-2023)
6.19.4 New England Biolabs (NEB) CRISPER-associated Nucleases Product Portfolio
6.19.5 New England Biolabs (NEB) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CRISPER-associated Nucleases Industry Chain Analysis
7.2 CRISPER-associated Nucleases Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CRISPER-associated Nucleases Production Mode & Process
7.4 CRISPER-associated Nucleases Sales and Âé¶¹Ô´´ing
7.4.1 CRISPER-associated Nucleases Sales Channels
7.4.2 CRISPER-associated Nucleases Distributors
7.5 CRISPER-associated Nucleases Customers
8 CRISPER-associated Nucleases Âé¶¹Ô´´ Dynamics
8.1 CRISPER-associated Nucleases Industry Trends
8.2 CRISPER-associated Nucleases Âé¶¹Ô´´ Drivers
8.3 CRISPER-associated Nucleases Âé¶¹Ô´´ Challenges
8.4 CRISPER-associated Nucleases Âé¶¹Ô´´ Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Âé¶¹Ô´´ Size Estimation
10.1.3 Âé¶¹Ô´´ Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
The Odin
Origene
Amsbio
Thermo Fisher Scientific
Merck
Boai Nky Medical Holdings Ltd
Biocompare
BioLabs, Inc.
Inscripta
Sherlock Biosciences
Editas
CRISPR Therapeutics
Synthego
Addgene
IDT (Integrated DNA Technologies)
Horizon Discovery
ToolGen
GenScript
New England Biolabs (NEB)
Ìý
Ìý
*If Applicable.
